190 related articles for article (PubMed ID: 37781288)
1. Investigation of red blood cell and platelet indices in adult dogs suffered from myxomatous mitral valve disease with and without pulmonary hypertension.
Tangmahakul N; Orton EC; Surachetpong SD
Front Vet Sci; 2023; 10():1234768. PubMed ID: 37781288
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
[TBL] [Abstract][Full Text] [Related]
3. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
Jang IS; Yoon WK; Choi EW
Ir Vet J; 2023 Feb; 76(1):3. PubMed ID: 36755290
[TBL] [Abstract][Full Text] [Related]
4. Iron parameters analysis in dogs with myxomatous mitral valve disease.
Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
[TBL] [Abstract][Full Text] [Related]
5. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
[TBL] [Abstract][Full Text] [Related]
6. Myxomatous mitral valve disease and associated pulmonary hypertension might increase serum angiopoietin-2 in dogs.
Yu H; Lee D; Chae Y; Choi M; Lee Y; Yun T; Kang BT; Yang MP; Kim H
Am J Vet Res; 2024 Jun; 85(6):. PubMed ID: 38531156
[TBL] [Abstract][Full Text] [Related]
7. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
[TBL] [Abstract][Full Text] [Related]
8. Platelet hyperresponsiveness and increased platelet-neutrophil aggregates in dogs with myxomatous mitral valve disease and pulmonary hypertension.
Duler L; Visser L; Nguyen N; Johnson LR; Stern JA; Li RHL
J Vet Intern Med; 2024 May; ():. PubMed ID: 38773707
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease.
Borgarelli M; Abbott J; Braz-Ruivo L; Chiavegato D; Crosara S; Lamb K; Ljungvall I; Poggi M; Santilli RA; Haggstrom J
J Vet Intern Med; 2015; 29(2):569-74. PubMed ID: 25818210
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
Sudunagunta S; Green D; Christley R; Dukes-McEwan J
J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary-vein-to-pulmonary-artery ratio can be utilized to evaluate myxomatous mitral valve disease progression in dogs.
Kim MS; Kim J; Seo MW; Park C
Am J Vet Res; 2024 Jul; 85(7):. PubMed ID: 38663446
[TBL] [Abstract][Full Text] [Related]
12. Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease.
Zhou Q; Cui X; Zhou H; Guo S; Wu Z; Li L; Zhang J; Feng W; Guo Y; Ma X; Chen Y; Qiu C; Xu M; Deng G
BMC Vet Res; 2023 Dec; 19(1):271. PubMed ID: 38087280
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of the serum in dogs with pulmonary hypertension secondary to myxomatous mitral valve disease: the preliminary study.
Sakarin S; Rungsipipat A; Roytrakul S; Jaresitthikunchai J; Phaonakrop N; Charoenlappanit S; Thaisakun S; Surachetpong SD
Front Vet Sci; 2024; 11():1327453. PubMed ID: 38596466
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
[TBL] [Abstract][Full Text] [Related]
15. Gut Dysbiosis and Its Associations with Gut Microbiota-Derived Metabolites in Dogs with Myxomatous Mitral Valve Disease.
Li Q; Larouche-Lebel É; Loughran KA; Huh TP; Suchodolski JS; Oyama MA
mSystems; 2021 Apr; 6(2):. PubMed ID: 33879495
[TBL] [Abstract][Full Text] [Related]
16. Myxomatous mitral valve disease in Labrador Retrievers and Golden Retrievers.
Wilson BA; Wesselowski S
J Am Vet Med Assoc; 2024 Jun; ():1-9. PubMed ID: 38906175
[TBL] [Abstract][Full Text] [Related]
17. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
[TBL] [Abstract][Full Text] [Related]
18. Red Blood Cell Distribution Width, Hematology, and Serum Biochemistry in Dogs with Echocardiographically Estimated Precapillary and Postcapillary Pulmonary Arterial Hypertension.
Mazzotta E; Guglielmini C; Menciotti G; Contiero B; Baron Toaldo M; Berlanda M; Poser H
J Vet Intern Med; 2016 Nov; 30(6):1806-1815. PubMed ID: 27747929
[TBL] [Abstract][Full Text] [Related]
19. Perivascular inflammatory cells and their association with pulmonary arterial remodelling in dogs with pulmonary hypertension due to myxomatous mitral valve disease.
Sakarin S; Rungsipipat A; Surachetpong SD
Vet Res Commun; 2023 Sep; 47(3):1505-1521. PubMed ID: 36976445
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
